Avalyn to Participate in the Jefferies Global Healthcare Conference
Avalyn (Nasdaq: AVLN) will present a company overview at the Jefferies Global Healthcare Conference in New York on June 4, 2026, from 9:55–10:25 a.m. ET.
Rhea-AI Summary
Avalyn (Nasdaq: AVLN) will present a company overview at the Jefferies Global Healthcare Conference in New York on June 4, 2026, from 9:55–10:25 a.m. ET. A live webcast and archived recording will be available on Avalyn’s investor relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – AVLN
On May 27, the day this news came out, AVLN closed 0.45% above the previous close.
Data tracked by StockTitan Argus for the May 27 session.
Key Figures
- Current price
- $26.94
- Pre-news market context for AVLN
- 24h move
- -7.42%
- Price change over prior 24 hours
- IPO shares sold
- 19,166,667 shares
- Aggregate common shares in IPO including overallotment
- Overallotment option
- 2,500,000 shares
- Underwriters’ option fully exercised in IPO
- IPO price
- $18.00 per share
- AVLN initial public offering price
- IPO gross proceeds
- $345 million
- Aggregate gross proceeds before fees and expenses
- Candid deal value
- Up to $2.2 billion
- UCB acquisition of Candid Therapeutics highlighted with AVLN IPO
- Candid upfront payment
- $2.0 billion
- Upfront portion of UCB–Candid acquisition
Historical Context
-
Announced upcoming EULAR 2026 long-term AP01 pulmonary fibrosis data.
-
Detailed AP01 usability and supportive-care posters at ATS 2026.
-
Highlighted UCB’s Candid deal and Avalyn’s inclusion among Vida IPOs.
-
Closed IPO and underwriters’ option, listing AVLN on Nasdaq.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will present a company overview at the Jefferies Global Healthcare Conference in New York City on June 4, 2026, at 9:55-10:25 a.m. ET.
Access to the live webcast of this event, and the archived recording, will be posted under the News & Events page of the Investor section of the company’s website at https://investors.avalynpharma.com/
About Avalyn Pharma
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and ongoing, multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA-IPF, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.
Investor Contact:
Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
ir@avalynpharma.com
Media Contact:
Kat Lippincott, Deerfield Group
kat.lippincott@deerfieldgroup.com
media@avalynpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.